News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
《大行》高盛降阿里健康(00241.HK)目標價至4.8元 評級「中性」 料AI投資拖累利潤
高盛發表研究報告，將阿里健康(00241.HK)目標價由5.2港元降至4.8港元，評級為「中性」，以反映AI及藥品類別投資增加影響盈利能力。報告指，阿里健康股價年初至今僅跌3%，跑贏恒生科技指數的11%跌幅，主要受惠於增長預期及AI醫療潛力。然而，該行預計公司下半年利潤將小幅倒退，扭轉上半年的利潤擴張趨勢，主要由於AI計劃投入增加，以及為應對競爭而加大原研藥...
Reset
Send
The window will close in 5 seconds
《大行》高盛降阿里健康(00241.HK)目標價至4.8元 評級「中性」 料AI投資拖累利潤
Close
Recommend
17
Positive
24
Negative
15
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

高盛發表研究報告，將阿里健康(00241.HK)  +0.120 (+2.733%)    Short selling $132.56M; Ratio 27.255%   目標價由5.2港元降至4.8港元，評級為「中性」，以反映AI及藥品類別投資增加影響盈利能力。

報告指，阿里健康股價年初至今僅跌3%，跑贏恒生科技指數的11%跌幅，主要受惠於增長預期及AI醫療潛力。然而，該行預計公司下半年利潤將小幅倒退，扭轉上半年的利潤擴張趨勢，主要由於AI計劃投入增加，以及為應對競爭而加大原研藥折扣力度。AI投資預期將延續至2027財年。

該行下調阿里健康2026至2028財年經調整淨利潤預測9%至11%，反映創新藥及AI投資增加。(ec/)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-14 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.